Using CSF protein markers to predict outcomes of shunt surgery in hydrocephalus patients
Official title: Alterations of CSF Protein Markers as Prognostic Indicator of the Response to Cerebrospinal Fluid Shunting in Chronic Hydrocephalus in Adults
Run by University of Valencia · NCT05915000 · Data updated 2026-11-12
This study is testing if certain protein markers in spinal fluid can help predict how well shunt surgery will work for adults with chronic hydrocephalus.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | University of Valencia Academic / other |
| Locations | 2 sites (Valencia, Valencia and 1 other locations) |
| Status | Recruiting |
| Started | June 13, 2019 |
| Main results expected | March 17, 2029 |
| Study ends | December 2029 |
| Registry record updated | April 22, 2026 |
| Trial ID | NCT05915000 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older diagnosed with chronic adult hydrocephalus.
✕Probably not a fit
Patients with conditions such as cerebrovascular disease, Alzheimer's disease, or other forms of dementia unrelated to chronic hydrocephalus may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the prognostic value of cerebrospinal fluid (CSF) protein markers, specifically beta-amiloid and phospho-tau proteins, in predicting the response to CSF shunt surgery in patients with chronic hydrocephalus. The study will involve assessing ventricular size and cognitive and motor impairments before and after the shunt procedure. By analyzing these protein markers, researchers hope to identify which patients are likely to benefit from the surgery and which may not experience significant improvement. The study will include patients diagnosed with adult chronic hydrocephalus based on clinical and neuroimaging criteria.
Why it matters
Potential benefit: If successful, this study could help tailor treatment plans for hydrocephalus patients, improving surgical outcomes and quality of life.
How similar studies have gone: While the approach of using CSF protein markers is promising, it remains relatively novel and has not been extensively tested in similar studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Minimum age of 18 years, there is no maximum age, especially if it is understood that this pathology is more frequent as one advance in age, especially among males; pathology compatible with chronic adult hydrocephalus Exclusion Criteria: * All patients whose suspected diagnosis is not adult chronic hydrocephalus will be excluded, specifically those with cerebrovascular disease, dementia not due to adult chronic hydrocephalus, Alzheimer's disease, Parkinson's disease, and hereditary degenerative brain pathology. Huntington's chorea
Where it's running
-
Hospital General Universitario de Valencia
Valencia, Valencia, Spain Recruiting -
Vicente Vanaclocha
Valencia, Valencia, Spain Recruiting
Study contacts
- Study coordinator: Vicente Vanaclocha, Full Professor
- Email: vicente.vanaclocha@uv.es
- Phone: +34 963 13 18 00
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.